Azithromycin Combination Therapy for the Treatment of Severe Malaria

NCT01374126 | Completed Phase 2

• 1 other identifier: PR-11019
• Study Type: interventional
• Target: 75
• Locations: 1 country
• Sites: 1

Brief Summary

A randomized controlled trial to assess the safety and efficacy of azithromycin combination therapy for use in severe malaria. This pilot trial will be conducted in uncomplicated malaria patients in southeastern Bangladesh.

Conditions

Falciparum Malaria

Outcome Measures

Primary Outcomes (2)

• Safety and Tolerability (Number of Participants with Adverse Events)

  42 days

• Adequate Clinical and Parasitological Response (ACPR) on Days 28 and 42

  42 days

Study Arms (2)

Azithromycin-Artesunate

EXPERIMENTAL

Drug: Azithromycin + Artesunate

Control (artesunate alone)

ACTIVE COMPARATOR

Drug: Artesunate

Interventions

Artesunate DRUG

Artesunate alone

Control (artesunate alone)

Azithromycin + Artesunate DRUG

Combination of azithromycin + artesunate

Azithromycin-Artesunate

Eligibility Criteria

• Age: 8 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female participants with a diagnosis of acute falciparum malaria meeting all criteria listed below may be included in the study:
• Acute symptomatic falciparum malaria infection with a parasite density of 100 to 100,000 asexual parasites/uL as determined on the screening smear with fever (defined as ≥37.5ºC), or reported history of fever within the last 48 hours.
• Age: 8-65 years old
• Males or females. All females over the age of 12 are required to have a negative human chorionic gonadotropin (hCG) pregnancy test (urine). All females of childbearing potential (not surgically sterile, or less than two years menopausal) are required to use an acceptable method of contraception, such as implant, injectable, oral contraceptive(s) with additional barrier contraception, intrauterine device, sexual abstinence, or vasectomized partner, throughout the study
• Written informed consent obtained
• Willing to stay under close medical supervision for the study duration
• Otherwise healthy outpatients

You may not qualify if:

• Participants presenting with any of the following will not be included in the study:
• Mixed malaria infection on admission by malaria smear
• A previous history of intolerance or hypersensitivity to the study drugs artesunate, azithromycin or to drugs with similar chemical structures
• Malaria drug therapy administered in the past 30 days by history
• History of significant cardiovascular, liver or renal functional abnormality or any other clinically significant illness, which in the opinion of the investigator would place them at increased risk.
• Symptoms of severe vomiting (no food or inability to take food during the previous 8 hours).
• Signs or symptoms of severe malaria (as defined by WHO 2003)
• Unable and/or unlikely to comprehend and/or follow the protocol

Sponsors & Collaborators

• Medical University of Vienna: lead
• International Centre for Diarrhoeal Disease Research, Bangladesh: collaborator

Study Sites (1)

MARIB

Bāndarban, Bangladesh

Location

MeSH Terms

Conditions

Malaria, Falciparum

Interventions

Artesunate; Azithromycin

Condition Hierarchy (Ancestors)

Malaria; Protozoan Infections; Parasitic Diseases; Infections; Mosquito-Borne Diseases; Vector Borne Diseases

Intervention Hierarchy (Ancestors)

Artemisinins; Reactive Oxygen Species; Free Radicals; Inorganic Chemicals; Organic Chemicals; Sesquiterpenes; Terpenes; Hydrocarbons; Erythromycin; Macrolides; Polyketides; Lactones

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assoc. Prof. Dr.

Study Record Dates

• First Submitted: June 10, 2011
• First Posted: June 15, 2011
• Study Start: July 1, 2011
• Primary Completion: November 1, 2012
• Study Completion: November 1, 2012
• Last Updated: August 23, 2013

Record last verified: 2013-08

Locations

BA (1)